Multiple High-Grade and Rare Immune-Related Adverse Events in a Colon Cancer Patient with Genomic and Cytokine Profiling

References

• Siegel R , DeSantisC , JemalA. Colorectal cancer statistics, 2014. CA Cancer J. Clin.64(2), 104–117 (2014).
   PubMed Web of Science ®Google Scholar
• Crooke H , KobayashiM , MitchellBet al. Estimating 1- and 5-year relative survival trends in colorectal cancer (CRC) in the United States: 2004 to 2014. J. Clin. Oncol.36(4 Suppl.), 587–587 (2018).
   Web of Science ®Google Scholar
• Gentzler R , HallR , KunkPRet al. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy8(5), 583–600 (2016).
   PubMed Web of Science ®Google Scholar
• Postow MA , CallahanMK , WolchokJD. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol.33(17), 1974–1982 (2015).
   PubMed Web of Science ®Google Scholar
• Kawakami H , ZaananA , SinicropeFA. Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J. Gastrointest. Oncol.6(6), 676–684 (2015).
   PubMed Web of Science ®Google Scholar
• Postow MA , SidlowR , HellmannMD. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med.378(2), 158–168 (2018).
   PubMed Web of Science ®Google Scholar
• Weber JS , KahlerKC , HauschildA. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol.30(21), 2691–2697 (2012).
   PubMed Web of Science ®Google Scholar
• Abu-Shawer O , SinghP , YenulevichEet al. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. J. ImmunoTher. Cancer8(2), e000992 (2020).
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA , GevaR , TanTJet al. First-in-human Phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. J. ImmunoTher. Cancer9(8), e002863 (2021).
   PubMed Web of Science ®Google Scholar
• Spain L , WallsG , JulveMet al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann. Oncol.28(2), 377–385 (2017).
   PubMed Web of Science ®Google Scholar
• Kumar N , AbboudH. Iatrogenic CNS demyelination in the era of modern biologics. Mult. Scler.25(8), 1079–1085 (2019).
   PubMed Web of Science ®Google Scholar
• Perrinjaquet C , DesbailletsN , HottingerAF. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Curr. Opin. Neurol.32(3), 500–510 (2019).
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M , KimY , CroninH , RichardsA , GibneyG , WeberJS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res.22(4), 886–894 (2016).
   PubMed Web of Science ®Google Scholar
• Ganesh K , StadlerZK , CercekAet al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol.16(6), 361–375 (2019).
   PubMed Web of Science ®Google Scholar
• Le DT , KimTW , Van CutsemEet al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol.38(1), 11–19 (2019).
   PubMed Web of Science ®Google Scholar
• Morse MA , OvermanMJ , HartmanLet al. Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair–deficient metastatic colorectal cancer. Oncologist24(11), 1453–1461 (2019).
   PubMed Web of Science ®Google Scholar
• Schrock AB , OuyangC , SandhuJet al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann. Oncol.30(7), 1096–1103 (2019).
   PubMed Web of Science ®Google Scholar
• Osipov A , LimSJ , PopovicAet al. Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: a meta-regression analysis. Clin. Cancer Res.26(18), 4842–4851 (2020).
   PubMed Web of Science ®Google Scholar
• Hiratsuka S , NakamuraK , IwaiSet al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell2(4), 289–300 (2002).
   PubMed Web of Science ®Google Scholar
• Zhao F , EvansK , XiaoCet al. Stromal fibroblasts mediate anti–PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma. Cancer Immunol. Res.6(12), 1459–1471 (2018).
   PubMed Web of Science ®Google Scholar
• Das A , FanslowW , CerrettiD , WarrenE , TalaricoN , McGuireP. Angiopoietin/tek interactions regulate MMP-9 expression and retinal neovascularization. Lab. Invest.83(11), 1637–1645 (2003).
   PubMed Web of Science ®Google Scholar
• Dumas E , NeagoeP-E , McDonaldPP , WhiteM , SiroisMG. New insights into the pro-inflammatory activities of Ang1 on neutrophils: induction of MIP-1β synthesis and release. PLoS One11(9), e0163140 (2016).
   PubMed Web of Science ®Google Scholar
• Kathamuthu GR , MoideenK , BaskaranDet al. Tuberculous lymphadenitis is associated with altered levels of circulating angiogenic factors. Int. J. Tuberc. Lung Dis.22(5), 557–566 (2018).
   PubMed Web of Science ®Google Scholar
• Tyan K , BaginskaJ , BrainardMet al. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol. Immunother.70(8), 2209–2221 (2021).
   PubMed Web of Science ®Google Scholar